Comment by Feb. 17 for your feedback to be reviewed by the guideline development workgroup.

In addition to the intriguing potential of fMRI, there are several challenges in performing fMRI activation studies in cognitively impaired subjects such as clinical AD patients. For example ...

This change in clinician-reported probability of AD is also associated with meaningful improvements in downstream clinical care, including changes in plans for AD medications as well as additional ...

Drugs targeting amyloid plaques have failed to show efficacy in clinical trials. A new approach is needed to tackle AD ...